Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723484 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30890373 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL1070057 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30076247 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL8616589 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL1070055 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL17696519 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL4328805 | 0.98 | GSR (0.58) | GSRFOLH1DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL10439913 | 0.98 | GSR (0.58) | GSRFOLH1DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL1419587 | 0.98 | GSR (0.58) | GSRFOLH1DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250297300-A1 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-20250223627-A1 | FLUOROGENIC SUBSTRATES FOR AMINOPEPTIDASE DETECTION IN BIOFLUIDS | Sunbird Bio, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-20250215476-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR HEPATOCELLULAR CARCINOMA | Sunbird Bio, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20250197917-A1 | METHOD OF PROTEASE DETECTION | Sunbird Bio, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12305217-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250110130-A1 | EX VIVO PROTEASE ACTIVATION AND DETECTION | Sunbird Bio, Inc. | 2025-04-03 | — | — | US | disclosed |
| CN-119731239-A | Iodinated crosslinked hydrogels and methods of forming the same | 波士顿科学医学有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119731240-A | Iodine labeled hydrogels and precursors thereof with improved properties | 波士顿科学医学有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-11851697-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | GLYMPSE BIO, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230175037-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2023-06-08 | — | — | US | disclosed |
| US-11604193-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | GLYMPSE BIO, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022232124-A1 | TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220178935-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220128567-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2022-04-28 | — | — | US | disclosed |
| US-20220128546-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2022-04-28 | — | — | US | disclosed |
| EP-3665161-A1 | NEW TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019030284-A1 | NEW TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | GSR 2913/4885FOLH1 48/4885DPP8 41/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | GSR 2920/4885FOLH1 21/4885DPP8 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.